CN1795893A - Medication composition for treating hepatitis, prepartion method and application - Google Patents
Medication composition for treating hepatitis, prepartion method and application Download PDFInfo
- Publication number
- CN1795893A CN1795893A CN 200410081551 CN200410081551A CN1795893A CN 1795893 A CN1795893 A CN 1795893A CN 200410081551 CN200410081551 CN 200410081551 CN 200410081551 A CN200410081551 A CN 200410081551A CN 1795893 A CN1795893 A CN 1795893A
- Authority
- CN
- China
- Prior art keywords
- injection
- extract
- radix notoginseng
- present
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 169
- 238000000034 method Methods 0.000 title claims abstract description 28
- 208000006454 hepatitis Diseases 0.000 title claims description 42
- 239000000203 mixture Substances 0.000 title claims description 29
- 231100000283 hepatitis Toxicity 0.000 title claims description 24
- 229940079593 drug Drugs 0.000 title description 50
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 69
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 69
- 239000007924 injection Substances 0.000 claims description 128
- 238000002347 injection Methods 0.000 claims description 128
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 114
- 239000000284 extract Substances 0.000 claims description 76
- 238000002360 preparation method Methods 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000005325 percolation Methods 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 17
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 16
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 16
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- 230000006837 decompression Effects 0.000 claims description 15
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 15
- 238000004064 recycling Methods 0.000 claims description 15
- 238000010828 elution Methods 0.000 claims description 14
- 150000002989 phenols Chemical class 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 11
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 229930182490 saponin Natural products 0.000 claims description 10
- 150000007949 saponins Chemical class 0.000 claims description 10
- 235000017709 saponins Nutrition 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 9
- 230000014759 maintenance of location Effects 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 230000000274 adsorptive effect Effects 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- -1 filters Substances 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000007639 printing Methods 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229940126701 oral medication Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 6
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 85
- 210000004369 blood Anatomy 0.000 description 45
- 239000008280 blood Substances 0.000 description 45
- 230000009467 reduction Effects 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 32
- 206010067125 Liver injury Diseases 0.000 description 29
- 238000012360 testing method Methods 0.000 description 26
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 23
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 23
- 210000004185 liver Anatomy 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- 210000003494 hepatocyte Anatomy 0.000 description 21
- 230000006378 damage Effects 0.000 description 18
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 230000003908 liver function Effects 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 230000005856 abnormality Effects 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 230000007850 degeneration Effects 0.000 description 12
- 231100000753 hepatic injury Toxicity 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000000630 rising effect Effects 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 231100000439 acute liver injury Toxicity 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 231100001252 long-term toxicity Toxicity 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000001466 anti-adreneric effect Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000035568 catharsis Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 206010019692 hepatic necrosis Diseases 0.000 description 4
- 230000007866 hepatic necrosis Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 230000003448 neutrophilic effect Effects 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000008087 TBil Methods 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 235000009048 phenolic acids Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 238000008715 DBil Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019727 Hepatitis acute Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- FPLYNRPOIZEADP-UHFFFAOYSA-N octylsilane Chemical group CCCCCCCC[SiH3] FPLYNRPOIZEADP-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Substances OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine for treating hepatitides by oral taking or injecting is prepared from red sage root and notoginseng. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of hepatitis, specifically, relating to Chinese medicine is the pharmaceutical composition of treatment hepatitis of feedstock production, belongs to the field of Chinese medicines.
Background technology
Liver is one of internal organs of wanting of body weight for humans, and theory of Chinese medical science is thought, main catharsis and main store blood are the major physiological functions of liver.Liver controlling conveyance and dispersion means that liver has diastole, carries out, transfers to reach, declare and loose, circulate to keep the smooth effect of whole body mechanism of qi a surname.The normal performance of this function can be regulated spiritual feelings will, makes the people in high spirits, and is happy; But facilitating digestion absorbs again, coordinates the taste ascending or descending movement of vital Qi; Can also keep the operation of QI and blood, regulate the metabolism of water liquid.Liver storing blood is meant that liver has storage blood again and regulates the effect of blood volume.The blood that liver is hidden is the material base of its catharsis function, and catharsis is again the function performance of store blood.Catharsis normal relies moistening of cloudy blood foster entirely; The operation of blood is unobstructed, be unable to do without the adjusting of irritability again.In case the liver failing to maintain the normal flow of QI, the resistance of the liver blood stasis of blood then appears in depression and stagnation of QI, and dysfunction of the spleen in transportation stops in the expectorant water, and then causes the enlargement of liver body, and the side of body is the convulsion pain down, and liver function waits pathological change unusually.
At present, " antihepatitis drug " of western medical treatment clinical practice mainly contains three major types: antiviral agents, immunomodulator and hepatoprotective medicine (vitamin medicaments, have function of detoxification class medicine, promote energy metabolism class medicine, promote protein synthesis class medicine).Antiviral agents mainly contains interferons antiviral agents and ucleotides antiviral agents, and clinical practice mainly contains interferon and lamivudine; The main clinical practice of immunomodulator thymosin, lentinan etc. are arranged; The clinical practice of hepatoprotective medicine mainly contain diammonium glycyrrhizinate (diammonium glycyrrhizinate), kurarinone etc.But, often all be to carry out symptomatic treatment clinically at the abnormal liver function symptom because the treatment of the nosetiology of viral hepatitis does not still have breakthrough so far.
In the Chinese medicine of the abnormal liver function that hepatitis etc. is caused, be the main rule of treatment with clearing away heat and eliminating dampness, blood circulation promoting and blood stasis dispelling, strengthening the body resistance.Wherein,, can contain medical material Radix Salviae Miltiorrhizae, Radix Notoginseng etc., hepatitis is presented following treatment characteristics based on the Chinese medicine of blood circulation promoting and blood stasis dispelling: 1. recover liver function better, very fast, have and significantly fall enzyme, the turbid descending, fall the red matter effect of gallbladder; 2. the liver spleen that bounces back improves stasis of blood disease; 3. anti-hepatic fibrosis; 4. stimulated hepatic cell regeneration.Present existing Chinese patent medicine product all is oral crude preparation by using basically, does not see effective site injection dosage form.Because liver is the detoxifcation organ of human body, many medicines need through liver metabolism, in treating hepatitis, take a large amount of medicines and usually increase the weight of the burden of liver, need refining the purification, reduce the consumption of taking medicine, and crude preparation by using is non-active ingredients more than 90%, and being absorbed in the body to increase very big burden to liver; Simultaneously, most of patients is because of the hepatitis acute attack clinically, obvious liver injury occurs and is admitted to hospital and seeks medical advice, and is dangerously ill this moment, changes rapidly, case fatality rate is high.Therefore,, suddenly wait to develop the oral formulations of making and the injection formulation of effective site or effective ingredient, with efficacy enhancing and toxicity reducing and rapid performance therapeutical effect at acute abnormal liver function patient.
Now contain Radix Salviae Miltiorrhizae, Radix Notoginseng material medicine preparation, comprise oral formulations and injection, as Radix Salviae Miltiorrhizae Injection, FUFANG DANSHEN DIWAN etc. interior, all without the extraction purification process of strictness, effective site content is lower, and the function of report cures mainly with indication and is used for the treatment of cardiovascular and cerebrovascular vessel.At present, report (Wu Shanming etc., Radix Notoginseng injection for treating blood stasis type chronic hepatitis and hemorheological preliminary observation thereof, the journal of shanghai Chinese medicine 1983 of the oral or injection for curing hepatitis B of two flavor crude drug injected or contained to existing Radix Salviae Miltiorrhizae and Radix Notoginseng respectively; 8,14; Tong Shaohong, the treatment of Radix Salviae Miltiorrhizae acupoint injection therapy is moved, chronic hepatitis 39 routine short term effects are observed Fujian medical journal 1980; 1,50; Hu Zhiming. Hu gold bead, the development of YIGANBAO electuary and observation of curative effect, modern Chinese medicine research and practice, 1996 03 phases; Xu Liming., " Radix Astragali detoxifcation blood activating decoction " treatment chronic viral hepatitis B 107 examples, the Jiangsu traditional Chinese medical science, 2000 10 phases; The flat liver heat removing soup treatment of bavin hepatitis A 146 examples, the practical Chinese and western medicine magazine of China, 2002 01 phases), but because Chinese medicine ingredients complexity, the effect difference that medical material is brought into play in preparation, and in the Chinese medicine single medicine and extract are mixed use, may produce unpredictable drug effect and toxicity, since the particularity of Chinese medicine medication, the medicament selection difference, the consumption difference, route of administration difference, drug effect are also different, therefore, so far do not see the report that has Radix Salviae Miltiorrhizae, Radix Notoginseng to share the injection for curing hepatitis B, do not have raw material Radix Salviae Miltiorrhizae, Radix Notoginseng compatibility to use the report of treatment hepatitis yet.
Summary of the invention
Technical scheme of the present invention has provided a kind of treatment hepatitis pharmaceutical composition, particularly, be a kind of be the pharmaceutical composition of the treatment hepatitis of feedstock production with Chinese crude drug Radix Salviae Miltiorrhizae, Radix Notoginseng, the present invention also provides this preparation of drug combination method and purposes.
The invention provides a kind of pharmaceutical composition for the treatment of hepatitis, it is the medicament that is prepared from by the following weight proportion raw material:
Radix Salviae Miltiorrhizae 3-10 part, Radix Notoginseng 1-3 part.
Wherein, Radix Salviae Miltiorrhizae is the dry root and rhizome of labiate Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bge.; Radix Notoginseng is the dry root of panax araliaceae plant Panax notoginseng (Burk.) F.H.Chen.
Further, it be by following weight proportion raw material preparation and medicament:
6 parts of Radix Salviae Miltiorrhizaes, 1 part of Radix Notoginseng.
This pharmaceutical composition is to be active component by water extract of medical material Radix Salviae Miltiorrhizae, Radix Notoginseng or alcohol extract, adds the medicament that acceptable accessories or complementary composition are prepared from.
Described medicament is oral formulations or injection.
Further, described oral formulations is capsule, tablet, pill, granule, powder; Described injection is injection water injection, quiet drop type, injectable powder.
Wherein, described injection contains salvia-soluble total phenols 3.24～3.36mg, total saponins 1.69～1.76mg, danshensu 0.83～0.91mg, protocatechualdehyde 0.23～0.25mg, ginsenoside Rg1 0.63～0.69mg for every milliliter.
Wherein, the HPLC finger printing of this pharmaceutical composition is made up of 4 characteristic peaks as shown in Figure 1,
Wherein chromatographic condition is: octadecylsilane chemically bonded silica is a filler; Methanol-acetonitrile-1.67% formic acid solution (volume ratio 23: 7: 70) is a mobile phase; The detection wavelength is 286nm.
Further, the relative standard deviation RSD of described 4 total peak relative retention time is all less than 10.0%, wherein, and No. 1 average relative retention time RT0.134% in peak, No. 2 peak RT0.184, No. 3 peak RT0.724, No. 4 peaks 1.000.
The present invention also provides this preparation of drug combination method, comprises the following steps:
A, take by weighing raw material: Radix Salviae Miltiorrhizae 3-10 part, Radix Notoginseng 1-3 part by each weight proportion;
The preparation of b, Radix Salviae Miltiorrhizae extract: the material Radix Salviae Miltiorrhizae of getting it filled, decoct with water extraction, to filter, filtrate concentrates, drying, the powdered extract powder is made solvent with 50-95% ethanol, and percolation extracts, and gets percolate, adds active carbon, heating and refluxing extraction, filter, reclaim ethanol, be dissolved in water, aqueous solution passes through D
101Macroporous adsorbent resin is used the 30-85% ethanol elution, and ethanol elution reclaims ethanol and promptly gets Radix Salviae Miltiorrhizae extract;
The preparation of c, Radix Notoginseng extract: the material Radix Notoginseng of getting it filled is a solvent with 35-95% ethanol, and percolation extracts, and gets percolate, to add active carbon in the percolate, reflux, extract, filters decompression filtrate recycling ethanol, get pure extractum, pure extractum is dissolved in water, filter, aqueous solution passes through D
101Macroporous adsorptive resins, reuse 30-90% ethanol elution effective site gets ethanol elution, and decompression recycling ethanol promptly gets Radix Notoginseng extract;
D, the Radix Salviae Miltiorrhizae extract of step b preparation, the Radix Notoginseng extract of step c preparation are mixed, be dissolved in water, add acceptable accessories or complementary composition, be prepared into preparation pharmaceutically commonly used.
Wherein, the d step is that the Radix Salviae Miltiorrhizae extract of step b, step c preparation, Radix Notoginseng extract are mixed, and is dissolved in water, and adds oral formulations pharmaceutically commonly used adjuvant commonly used and gets drug composition oral preparation of the present invention; Or
Steps d is that the Radix Salviae Miltiorrhizae extract of step b, step c preparation, Radix Notoginseng extract are mixed, and is dissolved in water, and adds injection pharmaceutically commonly used additives commonly used, and adjust pH is 5.5～6.5, promptly gets drug combination injection of the present invention.
The present invention also provides the purposes of each materials of weight proportions in the medicine of the acute and chronic hepatitis of preparation treatment.
Further, the purposes of each materials of weight proportions in the medicine of the acute and chronic hepatitis of preparation oral medication.
Further, the purposes of each materials of weight proportions in the medicine of the acute and chronic hepatitis of preparation injection for curing.
Further, each materials of weight proportions is treated purposes in the medicine of acute and chronic hepatitis in the preparation intravenous injection.
Pharmaceutical composition composition of raw materials of the present invention instructs based on Chinese medical theory, select medicine reasonable, precise and appropriate, Radix Salviae Miltiorrhizae in the side, bitter in the mouth is slightly cold, nontoxic, have cold and heat and gather ， Po Disorder, end stuffy sensation with restlessness except that abdominal mass, the QI invigorating effect, blood stasis dispelling is difficult for consumption and hinders healthy energy by heresy, and can promote nutrient blood new life, is suitable for clothes of a specified duration, and be difficult for causing untoward reaction, modern study shows: Radix Salviae Miltiorrhizae not only has many-sided pharmacological action to cardiovascular and cerebrovascular vessel, microcirculation etc., and effect for reducing blood fat is preferably arranged, for liver, the hepatic injury that can protect multiple reason to cause also has anti-liver toxicity; Experimental cirrhosis there is preventive and therapeutic effect, also can promotes cell regeneration, suppress hepatic fibroplasia etc., so be used as monarch drug in the side.Radix Notoginseng, sweet, the little hardship of nature and flavor and wet partially.The master returns Liver Channel, has the merit (Higher Education Publishing House, course teaching materials geared to the 21st century " Chinese materia medica ") of benefiting qi and nourishing blood concurrently, and modern study shows, but the Radix Notoginseng blood fat reducing promotes hemopoietic, analgesia; Anti-liver injury improves the liver blood circulation, improves the chronic index of liver function, and raise immunity and strong effect etc. are arranged.Radix Notoginseng is in order to the power of the blood circulation promoting and blood stasis dispelling ， Xiao Disorder pain relieving of assisting Radix Salviae Miltiorrhizae, and sets upright gas, and the effect of replenishing QI and blood disappears full side and do not hinder, and pretends to be accessory drugs.Two crude drug proportionings are used, the effect of performance Synergistic.
Principal component is not too many owing to single medicinal material, and simultaneously the character of part effective ingredient is also unstable, and the oxidation polymerization of chemical constituent takes place the injection that Chinese medicine is mixed with easily, reduce curative effect of medication, even produce precipitation, the many untoward reaction of clinical appearance, even cause death.By extraction, the process for purification of drug regimen raw material of the present invention, the medicine composite for curing hepatitis of the present invention for preparing is extracted purification effective site, and the raw material consumption is few, taking convenience.Injection solution does not produce precipitation, steady quality; Intravenous injection has no side effect, safety, and can overcome the defective of aqueous injection.And pharmaceutical composition of the present invention adopts the quality of finger printing control injection, makes pharmaceutical composition of the present invention controlled, stable.
In sum, medicine of the present invention is the preparation of feedstock production with Radix Salviae Miltiorrhizae, Radix Notoginseng, extract salvia-soluble total phenols in the medical material, Radix Notoginseng total arasaponins mixing had both reduced dosage, remove impurity simultaneously, dosage is more accurate, treatment hepatitis good effect, safe, controlled, stable is the clinical selection that a kind of new treatment hepatitis medicament is provided.
Obviously, according to foregoing of the present invention,,, can also make modification, replacement or the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.
The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
Description of drawings
Fig. 1 pharmaceutical composition HPLC of the present invention finger printing, wherein, No. 1 peak retention time RT is: 3.950min, No. 2 peak retention time RT5.425min, No. 3 peak retention time RT21.892min, No. 4 peak retention time 30.533min.
The specific embodiment
The preparation of the quiet drop type of embodiment 1 pharmaceutical composition of the present invention
A, get Radix Salviae Miltiorrhizae 1000g, cut sheet, add 8 times of water gagings and decoct and extract 4 times, decocted 1.5 hours at every turn, collecting decoction filters, and filtrate is concentrated into the clear paste of relative density about 1.05 (60 ℃ of heat are surveyed), spray drying, extract powder.Get extract powder and 3 times of amount kieselguhr mixings, the percolation under photograph fluid extract and the extractum item (" an appendix I of Chinese pharmacopoeia version in 2000 O), make solvent with 92% ethanol, flood after 4 hours,, collect percolate 15000ml with the speed of per minute 3ml percolation slowly, add active carbon 50g, reflux 60 minutes is put cold, filter, decompression filtrate recycling ethanol adds water 2500ml and makes dissolving to doing, and leaves standstill 24 hours, filter, filtrate is passed through the good D of pretreatment
101Macroporous adsorptive resins adds water 5000ml eluting, discards water lotion, continues with 50% ethanol 20000ml eluting, collects 50% ethanol elution, and decompression recycling ethanol promptly gets Radix Salviae Miltiorrhizae extract, and this Radix Salviae Miltiorrhizae extract is the salvia-soluble total phenols.
Wherein water boiling and extraction technology salvia-soluble total phenols, danshensu, the protocatechualdehyde rate of transform be all more than 95%, and dried cream yield is about 63%, and Radix Salviae Miltiorrhizae total phenolic acids content about 5.5% in the dried cream; The pre-impurity removal process salvia-soluble of ethanol percolation total phenols, danshensu, the protocatechualdehyde rate of transform be all more than 85%, and it is about 10% that dried cream yield is reduced to, and the salvia-soluble total phenol content about 35% in the dried cream; Extract obtained yield is about 3.0% behind the purification with macroreticular resin, and the water solublity total phenol content is about 85% in the extract, and content of Danshensu is about 25%, and protocatechualdehyde content is about 8%, has reached the requirement of vein with the injection new drug.
B, Radix Notoginseng are extracted purification: get Radix Notoginseng coarse powder 1000g, the percolation under photograph fluid extract and the extractum item (" an appendix I of Chinese pharmacopoeia version in 2000 Q), make solvent with 9 times of amount 65% ethanol, dipping spends the night, and with the speed percolation of per minute 5ml, collects percolate, add active carbon 30g, reflux 60 minutes is put coldly, filters, decompression filtrate recycling ethanol, add water 2500ml and make dissolving, filter, filtrate is passed through the good D of pretreatment
101Macroporous adsorptive resins is washed with water to cleaning mixture closely colourless (about 1200ml), discards washing liquid, continues with 50% ethanol elution of 11 times of amounts of medical material, collects eluent, and decompression recycling ethanol promptly gets Radix Notoginseng extract, and this Radix Notoginseng extract is a Radix Notoginseng total arasaponins.
Wherein ethanol percolate extraction technology Radix Notoginseng total arasaponins, ginsenoside Rg1's rate of transform be all more than 90%, and the extractum yield is about 20%, and content of the total saponins in radix notoginseng is about 45% in the extractum; The Radix Notoginseng extract yield of gained is about 8.5% behind the purification with macroreticular resin, and content of the total saponins in radix notoginseng has reached the requirement of vein with injection more than 90%.
C, get Radix Salviae Miltiorrhizae extract 3.3g, Radix Notoginseng extract 1.7g, add injection water 400ml and make dissolving, standby; Other gets sodium chloride for injection 9g, and sodium sulfite 0.2g adds injection water 100ml and makes dissolving, heated and boiled adds active carbon 0.2g, stirs evenly, continued to boil 15 minutes, and filtered filtrate and above-mentioned medicinal liquid mixing, add the injection water to 1000ml, the sodium hydroxide solution adjust pH to 6.0 with 10%, ultrafiltration is to clear and bright, be sub-packed in the 100ml infusion bottle, roll lid, sterilization, check clarity, packing, promptly.
The preparation method of embodiment 2 medicine injectable powder of the present invention
A, get Radix Salviae Miltiorrhizae 1000g, cut sheet, add 8 times of water gagings and decoct and extract 4 times, decocted 1.5 hours at every turn, collecting decoction filters, and filtrate is concentrated into the clear paste of relative density about 1.05 (60 ℃ of heat are surveyed), spray drying, extract powder.Get extract powder and 3 times of amount kieselguhr mixings, the percolation under photograph fluid extract and the extractum item (" an appendix I of Chinese pharmacopoeia version in 2000 O), make solvent with 92% ethanol, flood after 4 hours,, collect percolate 15000ml with the speed of per minute 3ml percolation slowly, add active carbon 50g, reflux 60 minutes is put cold, filter, decompression filtrate recycling ethanol adds water 2500ml and makes dissolving to doing, and leaves standstill 24 hours, filter, filtrate is passed through the good D of pretreatment
101Macroporous adsorptive resins adds water 5000ml eluting, discards water lotion, continues with 50% ethanol 20000ml eluting, collects 50% ethanol elution, and decompression recycling ethanol promptly gets Radix Salviae Miltiorrhizae extract, and this Radix Salviae Miltiorrhizae extract is the salvia-soluble total phenols.
Wherein water boiling and extraction technology salvia-soluble total phenols, danshensu, the protocatechualdehyde rate of transform be all more than 95%, and dried cream yield is about 63%, and Radix Salviae Miltiorrhizae total phenolic acids content about 5.5% in the dried cream; The pre-impurity removal process salvia-soluble of ethanol percolation total phenols, danshensu, the protocatechualdehyde rate of transform be all more than 85%, and it is about 10% that dried cream yield is reduced to, and the salvia-soluble total phenol content about 35% in the dried cream; Extract obtained yield is about 3.0% behind the purification with macroreticular resin, and the water solublity total phenol content is about 85% in the extract, and content of Danshensu is about 25%, and protocatechualdehyde content is about 8%, has reached the requirement of injectable powder new drug.
B, Radix Notoginseng are extracted purification: get Radix Notoginseng coarse powder 1000g, according to the percolation (an appendix I of Chinese Pharmacopoeia version in 2000 Q) under fluid extract and the extractum item, make solvent with 9 times of amount 65% ethanol, dipping spends the night, and with the speed percolation of per minute 5ml, collects percolate, add active carbon 30g, reflux 60 minutes is put coldly, filters, decompression filtrate recycling ethanol, add water 2500ml and make dissolving, filter, filtrate is passed through the good D of pretreatment
101Macroporous adsorptive resins is washed with water to cleaning mixture closely colourless (about 1200ml), discards washing liquid, continues with 50% ethanol elution of 11 times of amounts of medical material, collects eluent, and decompression recycling ethanol promptly gets Radix Notoginseng extract, and this Radix Notoginseng extract is a Radix Notoginseng total arasaponins.
Wherein ethanol percolate extraction technology Radix Notoginseng total arasaponins, ginsenoside Rg1's rate of transform be all more than 90%, and the extractum yield is about 20%, and content of the total saponins in radix notoginseng is about 45% in the extractum; The Radix Notoginseng extract yield of gained is about 8.5% behind the purification with macroreticular resin, and content of the total saponins in radix notoginseng has reached the requirement of injectable powder new drug more than 90%.
C, get Radix Salviae Miltiorrhizae extract 3.3g, Radix Notoginseng extract 1.7g, add injection water 400ml and make dissolving, standby; Injection supplementary material 100-200g puts in the sterile chamber in addition, adds injection water 450ml, stirs and makes dissolving, with above-mentioned medicinal liquid mixing, add the injection water and complement to 1000ml, be stirred to whole dissolvings gently, under positive pressure, with the micropore filter filtering liquid medicine of two polyphones, process spray drying under aseptic condition, make red seven sterilized powders, be sub-packed in the bottle, jump a queue, the jewelling lid, envelope bottle, sterilization, packing, promptly.
The preparation of embodiment 3 drug oral preparations of the present invention
A, get Radix Salviae Miltiorrhizae 1000g, cut sheet, add 8 times of water gagings and decoct and extract 4 times, decocted 1.5 hours at every turn, collecting decoction filters, and filtrate is concentrated into the clear paste of relative density about 1.05 (60 ℃ of heat are surveyed), spray drying, extract powder.Get extract powder and 3 times of amount kieselguhr mixings,, make solvent with 92% ethanol according to the percolation (an appendix I of Chinese Pharmacopoeia version in 2000 O) under fluid extract and the extractum item, flood after 4 hours,, collect percolate 15000ml with the speed of per minute 3ml percolation slowly, add active carbon 50g, reflux 60 minutes is put cold, filter, decompression filtrate recycling ethanol adds water 2500ml and makes dissolving to doing, and leaves standstill 24 hours, filter, filtrate is passed through the good D of pretreatment
101Macroporous adsorptive resins adds water 5000ml eluting, discards water lotion, continues with 50% ethanol 20000ml eluting, collects 50% ethanol elution, and decompression recycling ethanol promptly gets Radix Salviae Miltiorrhizae extract.
Wherein water boiling and extraction technology salvia-soluble total phenols, danshensu, the protocatechualdehyde rate of transform be all more than 95%, and dried cream yield is about 63%, and Radix Salviae Miltiorrhizae total phenolic acids content about 5.5% in the dried cream; The pre-impurity removal process salvia-soluble of ethanol percolation total phenols, danshensu, the protocatechualdehyde rate of transform be all more than 85%, and it is about 10% that dried cream yield is reduced to, and the salvia-soluble total phenol content about 35% in the dried cream; Extract obtained yield is about 3.0% behind the purification with macroreticular resin, and the water solublity total phenol content is about 85% in the extract, and content of Danshensu is about 25%, and protocatechualdehyde content is about 8%, has reached the requirement of injectable powder new drug.
B, Radix Notoginseng are extracted purification: get Radix Notoginseng coarse powder 1000g, according to the percolation (an appendix I of Chinese Pharmacopoeia version in 2000 Q) under fluid extract and the extractum item, make solvent with 9 times of amount 65% ethanol, dipping spends the night, and with the speed percolation of per minute 5ml, collects percolate, add active carbon 30g, reflux 60 minutes is put coldly, filters, decompression filtrate recycling ethanol, add water 2500ml and make dissolving, filter, filtrate is passed through the good D of pretreatment
101Macroporous adsorptive resins is washed with water to cleaning mixture closely colourless (about 1200ml), discards washing liquid, continues with 50% ethanol elution of 11 times of amounts of medical material, collects eluent, and decompression recycling ethanol promptly gets Radix Notoginseng extract.
Wherein ethanol percolate extraction technology Radix Notoginseng total arasaponins, ginsenoside Rg1's rate of transform be all more than 90%, and the extractum yield is about 20%, and content of the total saponins in radix notoginseng is about 45% in the extractum; The Radix Notoginseng extract yield of gained is about 8.5% behind the purification with macroreticular resin, and content of the total saponins in radix notoginseng has reached the requirement of injectable powder new drug more than 90%;
C, get Radix Salviae Miltiorrhizae extract 3.3g, Radix Notoginseng extract 1.7g, add water 300ml and make dissolving, standby; Oral formulations is put in the sterile chamber with adjuvant 100-200g in addition, adds water 400ml, stirs and makes dissolving, with above-mentioned medicinal liquid mixing, adds water and complements to 1000ml, is stirred to whole dissolvings gently, concentrates, and granulates drying.Make DANQI PIAN agent, granule or capsule, packing, sterilization.Packing, promptly.
The preparation of embodiment 4 injections of the present invention
Press the method for embodiment 1, the material Radix Salviae Miltiorrhizae 4000g that gets it filled, Radix Notoginseng 400g, the Radix Salviae Miltiorrhizae extract 13g of preparation gained, Radix Notoginseng extract 1g is prepared into aqueous injection.
The preparation of embodiment 5 injections of the present invention
Press the method for embodiment 1, the material Radix Salviae Miltiorrhizae 3000g that gets it filled, Radix Notoginseng 1000g, the Radix Salviae Miltiorrhizae extract 9.8g of preparation gained, Radix Notoginseng extract 1.8g is prepared into aqueous injection.
The preparation of embodiment 6 injections of the present invention
Press the method for embodiment 1, the material Radix Salviae Miltiorrhizae 5000g that gets it filled, Radix Notoginseng 2000g, the Radix Salviae Miltiorrhizae extract 16.6g of preparation gained, Radix Notoginseng extract 3.5g is prepared into aqueous injection.
The HPLC quantitative control methodin of embodiment 7 medicines of the present invention
Getting the pharmaceutical composition of the present invention of embodiment 1～3 preparation, according to high effective liquid chromatography for measuring, is filler with octadecylsilane chemically bonded silica; Methanol-acetonitrile-1.67% formic acid solution (volume ratio 23: 7: 70) is a mobile phase; The detection wavelength is 286nm.Its standard finger-print as shown in Figure 1.
The relative retention time of its standard finger-print is followed successively by 0.134 (1), and 0.184 (2), 0.724 (3), 1.000 (S), its relative deviation must not surpass 10%.
Embodiment 8 medicine quantitative control methodins of the present invention
1. water solublity total phenols
◆ instrument and reagent: Tianjin, island UV-2501 uv-spectrophotometric instrument; The reagent reagent is analytical pure; The danshensu sodium reference substance is available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute (lot number 0855-200102).
◆ analytical method: red seven injection liquid samples are diluted with water, and trap is measured in ferric chloride and the colour developing of potassium ferricyanide mixed solution at 770nm wavelength place, be contrast with the danshensu, adopts standard curve method to calculate content.
◆ methodological study: it is feasible to prove conclusively this method through precision, repeatability, stability and application of sample recovery test.
◆ measurement result: see Table 1.
The red seven injection water solublity determining total phenol results of table 1
| Lot number | 020401 | 020415 | 020416 | Meansigma methods |
| Content (mg/ml) | 3.24 | 3.34 | 3.36 | 3.31 |
2. total saponins
◆ instrument and reagent: Tianjin, island UV-2501 uv-spectrophotometric instrument; The reagent reagent is analytical pure; Ginsenoside Rg1's reference substance provides (lot number 0703-200015) by Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
◆ analytical method: red seven injection are with n-butanol extraction, and dissolve with ethanol dilutes, and vanillin-perchloric acid colour developing is measured trap at 551nm wavelength place, be contrast with ginsenoside Rg1, adopts standard curve method to calculate content.
◆ methodological study: it is feasible to prove conclusively this method through precision, repeatability, stability and application of sample recovery test.
◆ measurement result: see Table 2.
The red seven injection total saponins measurement results of table 2
| Lot number | 020401 | 020415 | 020416 | Meansigma methods |
| Content (mg/ml) | 1.76 | 1.69 | 1.73 | 1.72 |
3. danshensu and protocatechualdehyde
◆ instrument and reagent: Tianjin, island LC-10A high performance liquid chromatograph, SPD-10AV UV-detector.Methanol in the mobile phase is chromatographically pure, and other reagent reagents are analytical pure.Danshensu sodium, protocatechualdehyde reference substance provide available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute that (lot number is respectively 0855-200102,0810-200004).
◆ analytical method: red seven injection thin ups are as need testing solution, and the HPLC method is measured.Chromatographic column is selected Shimpack CLC-ODS post for use; Mobile phase is methanol-0.5% glacial acetic acid solution (11: 89); Detect wavelength 280nm; External standard method is calculated content.
◆ methodological study: it is feasible to prove conclusively this method through precision, repeatability, stability and application of sample recovery test.
◆ measurement result: see Table 3.
Red seven injection danshensus of table 3 and protocatechualdehyde measurement result
| Lot number | 020401 | 020415 | 020416 | Meansigma methods | |||
| Danshensu (mg/ml) protocatechualdehyde (mg/ml) | 0.89 0.24 | 0.91 0.25 | 0.84 0.24 | 0.83 0.24 | 0.86 0.23 | 0.84 0.25 | 0.86 0.24 |
4. ginsenoside Rg1
◆ instrument and reagent: Tianjin, island LC-10A high performance liquid chromatograph, SPD-10AV UV-detector.Ginsenoside Rg1's reference substance provides (lot number 0703-200015) by Nat'l Pharmaceutical ﹠ Biological Products Control Institute.Its high performance liquid chromatography main peak is single, and it is 99.8% that normalization method is measured purity.
◆ analytical method: red seven injection are directly as need testing solution, and the HPLC method is measured.The chromatographic column chromatographic column is selected octyl silane group silicagel column for use; Mobile phase is selected acetonitrile-0.05% phosphoric acid solution (19: 81) for use; Detect wavelength 203nm; External standard method is calculated content.
◆ methodological study: it is feasible to prove conclusively this method through precision, repeatability, stability and application of sample recovery test.
Measurement result: see Table 4.
The red seven injection ginsenoside Rg1 measurement results of table 4
| The sample lot number | 020401 | 020415 | 020416 |
| Ginsenoside Rg1 (mg/ml) | 0.69 | 0.64 | 0.63 |
Radix Salviae Miltiorrhizae and Radix Notoginseng all are the effective ingredient in the material medicine, therefore, simultaneously the composition in the two flavor crude drug are carried out quality control, and controllability is strong, more stable quality, controlled.
Below prove beneficial effect of the present invention by pharmacodynamics test.
Experimental example 1 anti-acute liver damage model test:
To rat acute liver injury model due to the CCL4, medicaments injection 17.0mg/kg of the present invention can raise significantly and the rising of AST (aspartate amino transferase) value has the reduction effect (P＜0.001, P＜0.01) of highly significant to ALT (alanine aminotransferase) value; 8.5mg/kg the reduction ALT value (P＜0.01) of energy highly significant.Medicaments injection 4.2,8.5 of the present invention, 17.0mg/kg have certain restitution to the damage hepatocyte, but nonsignificance (P＞0.05).Drug oral preparation of the present invention (embodiment 3 preparation) 21.0mg/kg can raise to ALT value to be had extremely significantly and the rising of AST value has the reduction effect (P＜0.001, P＜0.01) of highly significant; 10.5mg/kg the reduction ALT value (P＜0.01) of energy highly significant.Drug oral preparation 5.2,10.5 of the present invention, 21.0mg/kg have certain restitution to the damage hepatocyte, but nonsignificance (P＞0.05).
Table 5 medicaments injection of the present invention is to the influence of rat acute liver injury model due to the CCL4
| Group | Dosage (mg/kg) | Mus number (only) | 3h rat serum liver function after the administration (x ± SD) | |
| ALT(u/ml) | AST(u/ml) | |||
| The normal control group | Equal-volume | 10 | 48.6±10.8 | 122.3±26.8 |
| Model group | Equal-volume | 10 | 292.2±129.7▲▲▲ | 355.9±148.4▲▲▲ |
| Medicaments injection high dose group of the present invention | 17 | 10 | 82.6±26.3 *** | 185.4±43.4 *** |
| Dosage group in the medicaments injection of the present invention | 8.5 | 10 | 123.7±75.7 ** | 249.4±142.5 |
| Medicaments injection low dose group of the present invention | 4.2 | 10 | 233.3±108.2 | 454.7±153.9 |
Annotate: each administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
Model group and the comparison of normal control group ▲ ▲ ▲ P＜0.001 (sided t check)
As can be known from the above table: to rat acute liver injury model due to the CCL4, medicaments injection 17.0mg/kg of the present invention can raise to the ALT value to be had extremely significantly and the rising of AST value has the reduction effect (P＜0.001, P＜0.01) of highly significant; 8.5mg/kg the reduction ALT value (P＜0.01) of energy highly significant.Medicaments injection 4.2,8.5 of the present invention, 17.0mg/kg have certain restitution to the damage hepatocyte, but nonsignificance (P＞0.05).
To CCL4 induced mice acute liver damage model, medicaments injection 17.0mg/kg of the present invention can reduce ALT, AST value (P＜0.001, P＜0.001) extremely significantly; 8.5mg/kg reduction ALT, the AST value (P＜0.01) of energy highly significant; 4.2mg/kg can reduce ALP (alkali phosphatase) value (P＜0.05) significantly.4.2,8.5,17.0mg/kg has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.Drug oral preparation 21.0mg/kg of the present invention can reduce ALT, AST value (P＜0.001, P＜0.001) extremely significantly; 10.5mg/kg reduction ALT, the AST value (P＜0.01) of energy highly significant; 5.2mg/kg can reduce ALP value (P＜0.05) significantly.5.2,10.5,21.0mg/kg has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.
Table 6 medicaments injection of the present invention is to the influence of CCL4 induced mice acute liver damage model
| Group | Dosage (mg/kg) | Mus number (only) | 3h mice serum liver function test after the administration (x ± SD) | ||
| ALT(u/ml) | AST(u/ml) | ALP(u/ml) | |||
| The normal control group | Equal-volume | 10 | 39.8±18.5 | 113.9±26.1 | 154±32 |
| Model group | Equal-volume | 10 | 592.0±196.3▲▲▲ | 519.3±173.0▲▲▲ | 174±11 |
| Medicaments injection high dose group of the present invention | 17.0 | 10 | 118.5±59.5 *** | 191.5±72.4 *** | 171±40 |
| Dosage group in the medicaments injection of the present invention | 8.5 | 10 | 292.2±221.9 ** | 278.0±133.8 ** | 175±24 |
| Medicaments injection low dose group of the present invention | 4.2 | 10 | 445.8±215.1 | 471.8±158.2 | 148±37 * |
Annotate: each administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
Model group and the comparison of normal control group ▲ ▲ ▲ P＜0.001 (sided t check)
To CCL4 induced mice acute liver damage model, medicaments injection 17.0mg/kg of the present invention can reduce ALT, AST value (P＜0.001, P＜0.001) extremely significantly; 8.5mg/kg reduction ALT, the AST value (P＜0.01) of energy highly significant; 4.2mg/kg can reduce ALP value (P＜0.05) significantly.4.2,8.5,17.0mg/kg has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.
High as can be seen from the test of above dose-effect relationship, the dosage group more obvious than low dose group effect.
To ethanol induced mice acute liver damage model, medicaments injection 17.0mg/kg of the present invention has highly significant and reduces ALT extremely significantly and TB value effect (P＜0.01, P＜0.001); 8.5mg/kg significant reduction ALT value effect (P＜0.05) is arranged.Drug oral preparation 21.0mg/kg of the present invention has highly significant and reduces ALT extremely significantly and TB value effect (P＜0.01, P＜0.001); 10.5mg/kg significant reduction ALT value effect (P＜0.05) is arranged.
The anti-ethanol induced mice of table 7 medicaments injection of the present invention acute liver damage model test
| Group | Dosage (mg/kg) | Mus number (only) | 2.5h mice serum liver function test after the administration (x ± SD) | ||
| ALT(u/ml) | AST(u/ml) | TB(umol/ml) | |||
| The normal control group | -- | 10 | 49.7±8.8 | 181.2±18.4 | 3.32±1.17 |
| Model group | -- | 10 | 127.7±26.2▲ ▲▲ | 428.8±128.7 ▲▲▲ | 9.54±1.21▲▲ ▲ |
| Medicaments injection high dose group of the present invention | 17.0 | 10 | 95.6±18.8 ** | 365.0±82.7 | 5.96±21.8 *** |
| Dosage group in the medicaments injection of the present invention | 8.5 | 10 | 106.2±14.1 * | 427.5±200.7 | 8.49±2.82 |
| Medicaments injection low dose group of the present invention | 4.2 | 10 | 115.0±26.8 | 455.4±151.9 | 8.62±1.2 |
Annotate: each administration group and model group are relatively
*P＜0.05
*P＜0.01
* *P＜0.001
Model group and the comparison of normal control group ▲ ▲ ▲ P＜0.001 (sided t check)
To ethanol induced mice acute liver damage model, medicaments injection 17.0mg/kg of the present invention has highly significant and reduces ALT extremely significantly and TB value effect (P＜0.01, P＜0.001); 8.5mg/kg significant reduction ALT value effect (P＜0.05) is arranged.
To rat acute liver injury model due to the TAA (thioacetamide), medicaments injection 17.0mg/kg of the present invention can significantly reduce TBil value (P＜0.05); 8.5mg/kg can significantly reduce ALT value (P＜0.05); 4.2mg/kg ALT, AST and TBil are all had significant reduction effect (P＜0.05).4.2,8.5,17.0mg/kg all has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.Drug oral preparation 21.0mg/kg of the present invention can significantly reduce Tbil (total bilirubin) value (P＜0.05); 10.5mg/kg can significantly reduce ALT value (P＜0.05); 5.2mg/kg ALT, AST and TBil are all had significant reduction effect (P＜0.05).5.2,10.5,21.0mg/kg all has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.
To rat acute liver injury model due to the D-GLAN (D-Gal amine), the reduction ALT value (P＜0.01) that medicaments injection 17.0mg/kg of the present invention can highly significant, significantly reduce AST value (P＜0.025); 8.5mg/kg remarkable reduction ALT value effect (P＜0.05, P＜0.025) is arranged.8.5mg/kg the damage hepatocyte is had significant restitution (P＜0.05); 4.2,17.0mg/kg has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.Drug oral preparation 21.0mg/kg of the present invention can highly significant reduction ALT value (P＜0.01), significantly reduce AST value (P＜0.025); 10.5mg/kg remarkable reduction ALT value effect (P＜0.05, P＜0.025) is arranged.10.5mg/kg the damage hepatocyte is had significant restitution (P＜0.05); 5.2,21.0mg/kg has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.
To D-GLAN induced mice acute liver damage model, medicaments injection 17.0mg/kg of the present invention has remarkable and extremely significantly reduces ALT, ALP value effect (P＜0.025, P＜0.001); 8.5mg/kg reduction AST, ALT, the ALP value effect (P＜0.01, P＜0.05, P＜0.01) of remarkable and highly significant are arranged; Significantly and extremely significantly reduce ALT, ALP effect (P＜0.025, P＜0.001) 4.2mg/kg have.4.2,8.5,17.0mg/kg has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.Drug oral preparation 21.0mg/kg of the present invention has remarkable and extremely significantly reduces ALT, ALP value effect (P＜0.025, P＜0.001); 10.5mg/kg reduction AST, ALT, the ALP value effect (P＜0.01, P＜0.05, P＜0.01) of remarkable and highly significant are arranged; Significantly and extremely significantly reduce ALT, ALP effect (P＜0.025, P＜0.001) 5.2mg/kg have.5.2,10.5,21.0mg/kg has certain restitution, but nonsignificance (P＞0.05) to the damage hepatocyte.
The test of experimental example 2 anti-immune liver injury models
To the mouse immune liver damage model that bacterial endotoxin causes, medicaments injection 17.0mg/kg of the present invention has highly significant to reduce ALT effect (P＜0.01); 8.5mg/kg remarkable reduction ALT, AST effect (P＜0.05) are arranged.17.0mg/kg hepatic necrosis is had obvious reduction effect (P＜0.05); Can significantly increase liver cell proliferation (P＜0.05); 8.5mg/kg hepatocellular degeneration is had extremely significantly improvement effect (P＜0.001); 4.2mg/kg can extremely significantly improve hepatocellular degeneration, necrosis (P＜0.001); Can significantly improve hepatocellular inflammatory lesion (P＜0.05); Can extremely significantly increase liver cell proliferation (P＜0.001).Drug oral preparation 21.0mg/kg of the present invention has highly significant to reduce ALT effect (P＜0.01); 10.5mg/kg remarkable reduction ALT, AST effect (P＜0.05) are arranged.21.0mg/kg hepatic necrosis is had obvious reduction effect (P＜0.05); Can significantly increase liver cell proliferation (P＜0.05); 10.5mg/kg hepatocellular degeneration is had extremely significantly improvement effect (P＜0.001); 5.2mg/kg can extremely significantly improve hepatocellular degeneration, necrosis (P＜0.001); Can significantly improve hepatocellular inflammatory lesion (P＜0.05); Can extremely significantly increase liver cell proliferation (P＜0.001).
The test of experimental example 3 jaundice eliminatings
The rat obstructive jaundice model that right-ANIT causes, medicaments injection 17.0mg/kg of the present invention have remarkable reduction DBil, ALT and ALP value effect (P＜0.05); 8.5mg/kg can significantly reduce ALT and ALP value (P＜0.05); 4.2mg/kg can extremely significantly reduce the reduction ALP (P＜0.01) of ALT (P＜0.001), highly significant.Drug oral preparation 21.0mg/kg of the present invention has remarkable reduction DBil, ALT and ALP value effect (P＜0.05); 10.5mg/kg can significantly reduce ALT and ALP value (P＜0.05); 5.2mg/kg can extremely significantly reduce the reduction ALP (P＜0.01) of ALT (P＜0.001), highly significant.
The test of experimental example 4 immunologic functions
Medicaments injection 17.0mg/kg energy highly significant of the present invention and 4.2mg/kg can strengthen the effect (P＜0.01, P＜0.05) of mouse monokaryon cytophagy foreign body significantly, 17.0,8.5,4.2mg/kg to the acute liver damage model mice that D-GALN caused have respectively extremely significantly, highly significant and significantly strengthen its mononuclear cell and engulf the effect of foreign body (P＜0.001, P＜0.01, P＜0.05), have the enhance immunity effect.17.0mg/kg remarkable reduction ALT value effect (P＜0.025) is arranged.
Drug oral preparation 21.0mg/kg energy highly significant of the present invention and 5.2mg/kg can strengthen the effect (P＜0.01, P＜0.05) of mouse monokaryon cytophagy foreign body significantly, 21.0,10.5,5.2mg/kg to the acute liver damage model mice that D-GALN caused have respectively extremely significantly, highly significant and significantly strengthen its mononuclear cell and engulf the effect of foreign body (P＜0.001, P＜0.01, P＜0.05), have the enhance immunity effect.21.0mg/kg remarkable reduction ALT value effect (P＜0.025) is arranged.
The test of experimental example 5 anti-stress abilities
The effect that medicaments injection 8.5,17.0 of the present invention, 34.0mg/kg improved to the time-to-live of normal mouse under the normobaric hypoxia state, but do not have significance meaning (P＞0.05).34.0,17.0mg/kg can improve mice time-to-live (P＜0.01) in frozen water very significantly.
The effect that drug oral preparation 10.5,21.0 of the present invention, 42.0mg/kg improved to the time-to-live of normal mouse under the normobaric hypoxia state, but do not have significance meaning (P＞0.05).42.0,21.0mg/kg can improve mice time-to-live (P＜0.01) in frozen water very significantly.
Experimental example 6 improves rheology test
To rat depression of liver-QI and the QI stagnated by cold model that epinephrine causes, medicaments injection 50.0mg/kg of the present invention has and reduces whole blood viscosity effect (P＜0.001) extremely significantly; To whole blood reduced viscosity and whole blood relative indices have extremely significantly, highly significant increase effect (P＜0.001, P＜0.01) 25.0,12.5mg/kg all has reduction whole blood viscosity effect (P＜0.01, P＜0.001) extremely remarkable, highly significant; Whole blood reduced viscosity and whole blood relative indices there are highly significant, increase effect (P＜0.01, P＜0.05) significantly.25.0mg/kg can be extremely significant and 12.5mg/kg can significantly reduce whole blood fibrin (P＜0.001, P＜0.05).Drug oral preparation 60.0mg/kg of the present invention has and reduces whole blood viscosity effect (P＜0.001) extremely significantly; To whole blood reduced viscosity and whole blood relative indices have extremely significantly, highly significant increase effect (P＜0.001, P＜0.01) 30.0,15.0mg/kg all has reduction whole blood viscosity effect (P＜0.01, P＜0.001) extremely remarkable, highly significant; Whole blood reduced viscosity and whole blood relative indices there are highly significant, increase effect (P＜0.01, P＜0.05) significantly.30.0mg/kg can be extremely significant and 15.0mg/kg can significantly reduce whole blood fibrin (P＜0.001, P＜0.05).
The test of experimental example 7 microcirculation improvement
Medicaments injection 50.0 of the present invention, 25.0mg/kg all can expand blood capillary caliber (P＜0.05) significantly; All the blood capillary caliber that can cause antiadrenergic drug significantly dwindles (P＜0.05).12.5,25.0,50.0mg/kg all can be significantly, highly significant and the utmost point be significantly to the influence of antiadrenergic drug to the blood fluidised form, has the effect (P＜0.05, P＜0.01, P＜0.001) of microcirculation improvement.
Drug oral preparation 60.0 of the present invention, 30.0mg/kg all can expand blood capillary caliber (P＜0.05) significantly; All the blood capillary caliber that can cause antiadrenergic drug significantly dwindles (P＜0.05).15.0,30.0,60.0mg/kg all can be significantly, highly significant and the utmost point be significantly to the influence of antiadrenergic drug to the blood fluidised form, has the effect (P＜0.05, P＜0.01, P＜0.001) of microcirculation improvement.
Experimental example 8 is repaired the damage hepatocyte and is promoted liver cell regeneration
To rat acute liver injury model due to the D-GLAN, medicaments injection 8.5mg/kg of the present invention has significant restitution (P＜0.05) to the damage hepatocyte; The mouse immune liver damage model that bacterial endotoxin is caused, medicaments injection 17.0mg/kg of the present invention has obvious reduction hepatic necrosis effect (P＜0.05), 8.5mg/kg have and extremely significantly improve hepatocellular degeneration effect (P＜0.001), 4.2mg/kg can extremely significantly improve hepatocellular degeneration, downright bad effect (P＜0.001), can also significantly improve hepatocellular inflammatory lesion effect (P＜0.05).Simultaneously, medicaments injection 17.0mg/kg of the present invention and 4.2mg/kg can significantly, extremely significantly promote liver cell proliferation effect (P＜0.05, P＜0.001).Drug oral preparation 10.5mg/kg of the present invention has significant restitution (P＜0.05) to the damage hepatocyte; The mouse immune liver damage model that bacterial endotoxin is caused, medicaments injection 21.0mg/kg of the present invention has obvious reduction hepatic necrosis effect (P＜0.05), 10.5mg/kg have and extremely significantly improve hepatocellular degeneration effect (P＜0.001), 5.2mg/kg can extremely significantly improve hepatocellular degeneration, downright bad effect (P＜0.001), can also significantly improve hepatocellular inflammatory lesion effect (P＜0.05).Simultaneously, drug oral preparation 21.0mg/kg of the present invention and 5.2mg/kg can significantly, extremely significantly promote liver cell proliferation effect (P＜0.05, P＜0.001).
In addition, rat acute liver injury model due to CCL4, the TAA, and the result of the test of CCL4, D-GLAN (D-Gal amine) induced mice acute liver damage model all shows, medicaments injection 4.2-17.0mg/kg of the present invention and drug oral preparation 5.2-21.0mg/kg of the present invention all have certain restitution to the damage hepatocyte, but nonsignificance (P＞0.05).
Above-mentioned pharmacodynamic study proves, medicaments injection of the present invention and oral formulations all cause that to multiple reason ALT, AST due to acute liver damage and the immunologic liver injury, the active rising of ALP, TB all have tangible reduction effect; Tectology hepatocellular degeneration, necrosis, inflammatory degree to hepatic injury have some improvement and the effect of hypertrophy hepatocyte; Jaundice rising due to the biliary obstruction there is certain regressive effect; Can improve intact animal and hepatic injury animal body cellular immunization regulating and controlling effect; Have and improve hemorheology and microcirculatory effect preferably, certain anti-stress effect is arranged.
The toxicity of Chinese medicine and anaphylaxis are the problems that is difficult to solve always, mainly due to containing a large amount of indefinite compositions in the Chinese crude drug.For estimating the reaction of its drug action and toxicity, said preparation has been carried out curing mainly relevant main pharmacodynamics with function, general pharmacology is learned, acute toxicity, long term toxicity (Beagle dog long term toxicity, rat long term toxicity) and specific safety experimental study, and division is as follows:
Experimental example 9 animal acute toxicity tests
Try to achieve medicaments injection of the present invention to the LD50 of ICR kind mouse mainline administration and credible 2684.81 (2554.52～2821.75) mg/Kg that is limited to of 95% thereof with the calculating of Biliss method; The LD50 of intraperitoneal injection and credible 2750.85 (2538.73～2980.70) mg/Kg that is limited to of 95% thereof.Try to achieve drug oral preparation of the present invention to the LD50 of ICR kind mouse stomach administration and credible 2879.81 (2684.57～3078.63) mg/Kg that is limited to of 95% thereof with the calculating of Biliss method.
Try to achieve medicaments injection of the present invention to the LD50 of SD rat intravenous injection administration and credible 2189.35 (2073.62～2311.53) mg/Kg that is limited to of 95% thereof with the calculating of Biliss method; The LD50 of intraperitoneal injection and credible 2682.58 (2493.14～2886.42) mg/Kg that is limited to of 95% thereof.Try to achieve drug oral preparation of the present invention to the LD50 of SD rat oral gavage administration and credible 2714.35 (2531.84～2916.45) mg/Kg that is limited to of 95% thereof with the calculating of Biliss method.
Dyspnea appears in animal behind the intravenous administration, symptoms such as movable minimizings, and the many death in back 30 minutes of injection of dead animal, the minimizing with dosage of dead quantity and time reduces and prolongs, anatomic observation, the visible pathological changes of no naked eyes.Surviving animals is recovered after 24 hours normally, and food ration and body weight do not have obvious minimizing, behind the execution animal, and all no abnormal discovery of perusal vitals (heart, liver, spleen, lung, kidney etc.).
Dyspnea appears in animal behind the intraperitoneal injection, symptoms such as movable minimizings, the many death in back 8 hours of injection of dead mouse; Rats death is how dead in back 12 hours of injection, and the minimizing with dosage of dead quantity and time reduces and prolongs, anatomic observation, the visible pathological changes of no naked eyes.Surviving animals is recovered after 48 hours normally, and food ration and body weight do not have obvious minimizing, behind the execution animal, and all no abnormal discovery of perusal vitals (heart, liver, spleen, lung, kidney etc.).
Dyspnea appears in animal behind the gastric infusion, and symptoms such as movable minimizing recover normal after 48 hours, and food ration and body weight do not have obvious minimizing, behind the execution animal, and all no abnormal discovery of perusal vitals (heart, liver, spleen, lung, kidney etc.).
Conclusion: above test shows that medicaments injection of the present invention and oral formulations safe dose scope are bigger.
Experimental example 10 long-term toxicity test for animals
1, Beagle dog long term toxicity test
Medicaments injection of the present invention is equivalent to 30,15 and 7.5 times of its clinical vein instillation dosage respectively by 250,125 and three dosage of 62.5mg/kg, and to Beagle dog intravenously administrable 45 days and drug withdrawal 15 days, the result was as follows continuously:
(1) growth promoter and ordinary circumstance are observed: observe with drug withdrawal during the administration, animal mental act, activity, fur, breathing, circulation, appetite, defecation etc. show no obvious abnormalities, between administration and withdrawal time, dog body weight gain and growth are not had obviously influence, do not have the retardance toxic reaction yet.
(2) routine urianlysis: no abnormality seen.
(3) to the influence of hemogram: no abnormality seen.
(4) to the influence of liver function: no abnormality seen.
(5) to the influence of renal function: no abnormality seen.
(6) to the influence of blood glucose and serum cholesterol: no abnormality seen.
(7) to Electrocardiographic influence: no abnormality seen.
(8) living animal bone marrow examination: no abnormality seen.
(9) system becomes celestial and organ index: no abnormality seen.
(10) histopathologic examination: administration checked that lymphatic nodule formed under the low dose group buck 1 routine mucous membrane of colon in 45 days; Low dose group jenny 1 routine lymph follicle increases, and comes across medullary substance.Administration group and matched group be no difference of science of statistics (P＞0.05) relatively.Drug withdrawal checked that each was organized the internal organs inspection and there is no unusually in 15 days.
Conclusion: medicaments injection of the present invention is given 45 days non-toxic reactions of Beagle dog intravenous drip 250mg/Kg continuously.250mg/Kg and following dosage show no obvious abnormalities influence to the every index of dog, also do not have obvious retardance toxic reaction, belong to the safe dose scope.
2, rat long term toxicity test data summary
Medicaments injection of the present invention is by 250,125 and three dosage of 62.5mg/kg, drug oral preparation of the present invention is by 630,157.5 and three dosage of 78mg/kg, be equivalent to 30,15 and 7.5 times of clinical daily dosage respectively, respectively continuously to rats by intraperitoneal injection administration 45 days and drug withdrawal 14 days, observed medicaments injection of the present invention and oral formulations and be the main adverse reaction of animal:
(1) ordinary circumstance and body weight: 14 days each groups of administration 45 days and drug withdrawal are tried the rat behavior activity normally, and the animal wool pool is smooth, no abnormal secretions.The weight of animals and food ration be normal growth in time, and each group does not all have animal dead.
(2) routine blood test: medicaments injection of the present invention is continuously to rats by intraperitoneal injection administration blood routine examination in 45 days, compare with matched group, female group of RBC of medicaments injection high and low dose of the present invention significantly raises (P＜0.05) respectively, female group of RBC highly significant rising of middle dosage (P＜0.01); Male group of PLT of high, medium and low dosage P＜0.001 that extremely significantly raises respectively); Female, male group of RC of high, medium and low dosage respectively significantly, highly significant and extremely significantly raise (P＜0.05, P＜0.01 and P＜0.001); Female group of MCHC of high, middle dosage highly significant respectively reduces (P＜0.01), all the other every index no abnormality seens (P＞0.05), and each organizes index all in normal range, and practical significance is not obvious.Drug withdrawal 14 days check with matched group relatively, female group of RBC of medicaments injection high dose of the present invention significantly reduces (P＜0.05), female group of PDW highly significant of middle dosage reduces (P＜0.01), each organizes index all in normal range, practical significance is not obvious.
Drug oral preparation group of the present invention is continuously to rats by intraperitoneal injection administration blood routine examination in 45 days, compare with matched group, female group of RBC of drug oral preparation group high and low dose of the present invention significantly raises (P＜0.05) respectively, female group of RBC highly significant rising of middle dosage (P＜0.01); Male group of PLT of high, medium and low dosage P＜0.001 that extremely significantly raises respectively); Female, male group of RC of high, medium and low dosage respectively significantly, highly significant and extremely significantly raise (P＜0.05, P＜0.01 and P＜0.001); Female group of MCHC of high, middle dosage highly significant respectively reduces (P＜0.01), all the other every index no abnormality seens (P＞0.05), and each organizes index all in normal range, and practical significance is not obvious.Drug withdrawal 14 days check with matched group relatively, female group of RBC of drug oral preparation group high dose of the present invention significantly reduces (P＜0.05), female group of PDW highly significant of middle dosage reduces (P＜0.01), each organizes index all in normal range, practical significance is not obvious.
(3) liver function: medicaments injection successive administration of the present invention was checked in 45 days, compared with matched group, and female group of TP of dosage has highly significant to raise (P＜0.01) in the medicaments injection of the present invention, and the liver function index of all the other each treated animals is all in normal range.Drug withdrawal was checked and the matched group inspection, and was not seen notable difference (P＞0.05) in 14 days.The liver function index of each treated animal is all in normal range.
Drug oral preparation group successive administration of the present invention was checked in 45 days, compared with matched group, and female group of TP of dosage has highly significant to raise (P＜0.01) in the drug oral preparation group of the present invention, and the liver function index of all the other each treated animals is all in normal range.Drug withdrawal was checked and the matched group inspection, and was not seen notable difference (P＞0.05) in 14 days.The liver function index of each treated animal is all in normal range.
(4) renal function: medicaments injection of the present invention, oral formulations group successive administration 45 days and 14 days kidney function test of drug withdrawal, compare with matched group, do not see notable difference (P＞0.05), each treated animal renal function index is all in normal range.
(5) other biochemical indicator: medicaments injection of the present invention, oral formulations group successive administration 45 days, compare with matched group, medicaments injection of the present invention, female group of CHOL of oral formulations group high and low dose significantly reduce (P＜0.05) respectively.Drug withdrawal was checked after 14 days, compared with matched group, did not see notable difference (P＞0.05).
(6) system becomes celestial and organ index: the result shows, administration 45 days and drug withdrawal 14 days, and medicaments injection of the present invention, each dosage group of oral formulations group and matched group compare, no significant difference (P＞0.05).
(7) histopathologic examination: administration 45 days and drug withdrawal 14 days, each dosage group of medicaments injection of the present invention and control rats brain (cerebellum), hypophysis, optic nerve, the heart, liver, spleen, lung, kidney, the adrenal gland, thyroid, pancreas, thymus, bladder, stomach, duodenum, ileum, colon, ovary, the uterus, testis, epididymis, prostate, lymph node, spinal cord, breastbone, nasal septum, amphiblestroid tectology inspection found that: 45 days medicaments injection high dose group buck 1 examples of the present invention of administration, middle dosage group jenny 1 routine stomach lower part vasodilation companion neutrophilic infiltration.High dose group buck 2 examples, jenny 1 example, middle dosage is female, lymphatic nodule forms under each 1 example of buck and the matched group buck 1 routine mucous membrane of colon.The obvious hemorrhage companion's monokaryon of high dose group buck 1 routine bladder with partial flesh layer, neutrophil cell soak into.High dose group 1 example is film and a little neutrophilic infiltration of flesh layer in utero.All the other respectively organize every index, all do not find tangible pathomorphology infringement.Administration group and matched group compare, no difference of science of statistics (P＞0.05).Drug withdrawal checked that each group was not all found tangible pathomorphology infringement in 14 days.
Histopathologic examination: administration 45 days and drug withdrawal 14 days, each dosage group of drug oral preparation group of the present invention and control rats brain (cerebellum), hypophysis, optic nerve, the heart, liver, spleen, lung, kidney, the adrenal gland, thyroid, pancreas, thymus, bladder, stomach, duodenum, ileum, colon, ovary, the uterus, testis, epididymis, prostate, lymph node, spinal cord, breastbone, nasal septum, amphiblestroid tectology inspection found that: 45 days drug oral preparation group high dose group buck 2 examples of the present invention of administration, middle dosage group jenny 1 routine stomach lower part vasodilation companion neutrophilic infiltration.High dose group buck 1 example, jenny 1 example, middle dosage is female, lymphatic nodule forms under each 1 example of buck and the matched group buck 1 routine mucous membrane of colon.The obvious hemorrhage companion's monokaryon of high dose group buck 1 routine bladder with partial flesh layer, neutrophil cell soak into.High dose group 1 example is film and a little neutrophilic infiltration of flesh layer in utero.All the other respectively organize every index, all do not find tangible pathomorphology infringement.Administration group and matched group compare, no difference of science of statistics (P＞0.05).Drug withdrawal checked that each group was not all found tangible pathomorphology infringement in 14 days.
Conclusion: medicaments injection of the present invention, heavy dose of lumbar injection of drug oral preparation group leader's phase of the present invention give animal subject and overt toxicity reaction and pathological lesion do not occur.
3, specific safety experimental data and study summary
3.1 hemolytic test
Medicaments injection of the present invention mixes with 2% rabbit erythrocyte suspension, incubation 4 hours, and haemolysis and coacervation do not appear in the result.
3.2 vascular stimulation test
Medicaments injection of the present invention is to rabbit auricular vein instillation 50mg/kg, and for three days on end, perusal does not have irritant reaction such as hyperemia, edema, degeneration, necrosis, and each structure of pathological tissue morphological examination is normal, shows that this medicine has no stimulation to the injection site blood vessel.
3.3 muscular irritation test
Medicaments injection of the present invention after 48 hours, is observed the irritant reaction situation to rabbit quadriceps femoris injection 1ml (5mg), and the result does not have irritant reaction such as hyperemia, edema, degeneration, shows that this medicine has no stimulation to injection site muscle.
3.4 whole body is hypersensitive test initiatively
Medicaments injection of the present invention is every 0.5ml sensitization of lumbar injection to Cavia porcellus the next day, totally 3 times, animal is respectively at injecting first behind the medicaments injection of the present invention the 14th day and the 21st day, intravenous injection medicaments injection 2ml of the present invention attacks, whole body active anaphylaxis symptom does not all appear in the result, positive reaction all appears in egg protein positive control treated animal, shows that this medicine does not cause allergic reaction.
3.5 depressor substance inspection
Medicaments injection of the present invention is that the blood pressure lowering experiment is carried out in contrast to anesthetized cat vena femoralis injection 8.3mg/kg with the histamine, and medicaments injection of the present invention does not as a result cause the blood pressure lowering reaction, shows that this medicine does not have hypotensive effect.
Brief summary: medicaments injection of the present invention does not produce haemolysis and aggregation, to muscle, blood vessel nonirritant, does not cause the whole body active anaphylaxis, and no hypotensive effect meets the requirement of injection Generally Recognized as safe.
Learn through the pharmacological toxicology of system and studies have shown that, medicaments injection of the present invention has multiple reason is caused that ALT, AST due to acute liver damage and the immunologic liver injury, the active rising of ALP, TB all have tangible reduction effect; Tectology hepatocellular degeneration, necrosis, the inflammatory degree of hepatic injury had some improvement and repair the hepatocyte effect; Jaundice rising due to the biliary obstruction there is the choleretic effect that necessarily disappears; Can improve intact animal and hepatic injury animal body cellular immunization regulating and controlling effect; Have and improve hemorheology and microcirculatory effect preferably, intact animal and hepatic injury animal are all had anti-stress effect effect preferably, for clinical practice provides the pharmacology foundation; In addition, acute toxicity test in mice, Beagle dog, rat long term toxicity test and general pharmacology are learned the experimental study result and are shown, the said preparation toxic reaction is low, and degree of safety is bigger, for its data for clinical drug use provides the toxicology foundation, each system of intact animal is not had influence, have no adverse reaction.The specific safety experimental study shows and meets the requirement of injection Generally Recognized as safe.
Medicine material compatibility of the present invention is determined with the side's of tearing open research through the pharmacodynamics screening, the medicaments injection preparation made from this material combination of the present invention proves that through drug effect and toxicological study the liver injury that a variety of causes is caused has stronger pharmacologically active, and toxic and side effects is lower.Though there is not the nosetiology therapeutical effect, applied widely to fall enzyme and to promote that liver cell regeneration is characteristic, can improve clinical symptoms rapidly, adopt oral formulations and injection dosage form can strengthen the means of tcm emergency treatment.
Claims (14)
1, a kind of pharmaceutical composition for the treatment of hepatitis is characterized in that: it is the medicament that is prepared from by the following weight proportion raw material:
Radix Salviae Miltiorrhizae 3-10 part, Radix Notoginseng 1-3 part.
2, the pharmaceutical composition of treatment hepatitis according to claim 1 is characterized in that: it is the medicament that is prepared from by the following weight proportion raw material:
6 parts of Radix Salviae Miltiorrhizaes, 1 part of Radix Notoginseng.
3, the pharmaceutical composition of treatment hepatitis according to claim 1 and 2, it is characterized in that: it is to be mixed into active component by water extract of medical material Radix Salviae Miltiorrhizae, Radix Notoginseng or alcohol extract, adds the medicament that acceptable accessories or complementary composition are prepared from.
4, the pharmaceutical composition of treatment hepatitis according to claim 3 is characterized in that: described medicament is oral formulations or injection.
5, the pharmaceutical composition of treatment hepatitis according to claim 4 is characterized in that: described oral formulations is capsule, tablet, pill, granule, powder.
6, the pharmaceutical composition of treatment hepatitis according to claim 4 is characterized in that: described injection is injection water injection, quiet drop type, injectable powder.
7, the pharmaceutical composition of treatment hepatitis according to claim 6 is characterized in that: contain salvia-soluble total phenols 3.24～3.36mg, total saponins 1.69～1.76mg, danshensu 0.83～0.91mg, protocatechualdehyde 0.23～0.25mg, ginsenoside Rg1 0.63～0.69mg in every milliliter of injection water injection.
8, according to the pharmaceutical composition of claim 6 or 7 described treatment hepatitis, it is characterized in that: it is characterized in that: the HPLC finger printing of this pharmaceutical composition is made up of 4 characteristic peaks as shown in Figure 1,
Wherein chromatographic condition is: octadecylsilane chemically bonded silica is a filler; Methanol-acetonitrile-1.67% formic acid solution, its volume ratio are 23: 7: 70 mobile phase; The detection wavelength is 286nm.
9, the pharmaceutical composition of treatment hepatitis according to claim 8, it is characterized in that: the relative standard deviation RSD of described 4 characteristic peak relative retention time is all less than 10.0%, wherein, No. 1 average relative retention time RT 0.134 in peak, No. 2 peak RT 0.184,0.724, No. 4 peak RT 1.000 of No. 3 peak RT.
10, a kind of method for preparing the pharmaceutical composition of the described treatment hepatitis of above-mentioned any claim, it comprises the following steps:
A, take by weighing raw material: Radix Salviae Miltiorrhizae 3-10 part, Radix Notoginseng 1-3 part by each weight proportion;
The preparation of b, Radix Salviae Miltiorrhizae extract: the material Radix Salviae Miltiorrhizae of getting it filled, decoct with water extraction, filter, filtrate concentrates, drying, and the powdered extract powder is made solvent with 50-95% ethanol, percolation extracts, and gets percolate, adds active carbon, heating and refluxing extraction filters, and reclaims ethanol, be dissolved in water, aqueous solution is used the 30-85% ethanol elution by macroporous adsorbent resin, ethanol elution reclaims ethanol and promptly gets Radix Salviae Miltiorrhizae extract;
The preparation of c, Radix Notoginseng extract: the material Radix Notoginseng of getting it filled is a solvent with 35-95% ethanol, and percolation extracts, get percolate, will add active carbon, reflux, extract, in the percolate, filter, decompression filtrate recycling ethanol gets pure extractum, pure extractum is dissolved in water, filters, aqueous solution passes through macroporous adsorptive resins, reuse 30-90% ethanol elution, get ethanol elution, reclaim ethanol, promptly get Radix Notoginseng extract;
D, the Radix Salviae Miltiorrhizae extract of step b preparation, the Radix Notoginseng extract of step c preparation are mixed, be dissolved in water, add acceptable accessories or complementary composition, be prepared into preparation pharmaceutically commonly used.
11, the purposes of the described following weight proportion raw material of claim 1 in the medicine of the acute and chronic hepatitis of preparation treatment: Radix Salviae Miltiorrhizae 3-10 part, Radix Notoginseng 1-3 part.
12, purposes according to claim 11 is characterized in that: described medicine is the medicine of the acute and chronic hepatitis of oral medication.
13, purposes according to claim 11 is characterized in that: described medicine is the medicine of the acute and chronic hepatitis of injection for curing.
14, purposes according to claim 13 is characterized in that: described medicine is the medicine that acute and chronic hepatitis is treated in intravenous injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100815511A CN100484543C (en) | 2004-12-21 | 2004-12-21 | Medicament composition for treating hepatitis, prepartion method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100815511A CN100484543C (en) | 2004-12-21 | 2004-12-21 | Medicament composition for treating hepatitis, prepartion method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1795893A true CN1795893A (en) | 2006-07-05 |
| CN100484543C CN100484543C (en) | 2009-05-06 |
Family
ID=36817348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100815511A Active CN100484543C (en) | 2004-12-21 | 2004-12-21 | Medicament composition for treating hepatitis, prepartion method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100484543C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107260803A (en) * | 2017-06-19 | 2017-10-20 | 上海华源安徽锦辉制药有限公司 | The preparation method of Sodium Danshensu content in a kind of raising red sage roo drip liquid |
| CN107441161A (en) * | 2017-06-19 | 2017-12-08 | 上海华源安徽锦辉制药有限公司 | A kind of preparation method of red sage roo drip liquid |
| EP4193996A1 (en) * | 2021-12-11 | 2023-06-14 | Mendel University in Brno | Ginsenosides for treatment of chronic hepatitis b virus infections |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089496A (en) * | 1993-01-06 | 1994-07-20 | 山东烟台西苑制药厂 | Compound sodium alginati diesteras |
| CN1168496C (en) * | 2002-01-09 | 2004-09-29 | 中国药科大学 | Powder snuff of insulin for administration of lung and its preparing process |
| CN1456188A (en) * | 2002-05-10 | 2003-11-19 | 徐希平 | Use of red rage root and notoginseng in preparation of medicine for prevention of cerebral apoplexy |
| CN1456187A (en) * | 2002-05-10 | 2003-11-19 | 徐希平 | Use of red sage root and notoginseng in preparation of medicine for prevention of acute coronary syndrome |
| CN1470255A (en) * | 2002-07-22 | 2004-01-28 | 王智民 | Preparation extracted from the root of red-rooted solvia and pseudo-ginseng and its compound preparation and medical use |
| CN1415303A (en) * | 2002-10-24 | 2003-05-07 | 成都浦泓生物科技开发有限公司 | Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia |
| CN100418534C (en) * | 2002-12-19 | 2008-09-17 | 上海博泰医药科技有限公司 | Traditional Chinese medicine active part compound preparation for curing cardiac and cerebral vascular diseases and its preparing method |
-
2004
- 2004-12-21 CN CNB2004100815511A patent/CN100484543C/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107260803A (en) * | 2017-06-19 | 2017-10-20 | 上海华源安徽锦辉制药有限公司 | The preparation method of Sodium Danshensu content in a kind of raising red sage roo drip liquid |
| CN107441161A (en) * | 2017-06-19 | 2017-12-08 | 上海华源安徽锦辉制药有限公司 | A kind of preparation method of red sage roo drip liquid |
| EP4193996A1 (en) * | 2021-12-11 | 2023-06-14 | Mendel University in Brno | Ginsenosides for treatment of chronic hepatitis b virus infections |
| WO2023104227A1 (en) * | 2021-12-11 | 2023-06-15 | Mendel University In Brno | Ginsenosides for treatment of chronic hepatitis b virus infections |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100484543C (en) | 2009-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN1742949A (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN1285358C (en) | Medicinal composition, preparation and quality control thereof | |
| CN1557842A (en) | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1803787A (en) | Hypericum perforatum L. total flavone extracts, its preparation and application | |
| CN1511544A (en) | Traditional Chinese medicine compound preparation for preventing and treating intestinal adhesion and preparing method | |
| CN1872199A (en) | Composition of Chinese traditional medicine, and preparation method | |
| CN1186051C (en) | 'Huajuhong' preparation and its preparing process | |
| CN1206236C (en) | Manyprickle acanthopanax general saponin extractive and its medicinal composition | |
| CN1795893A (en) | Medication composition for treating hepatitis, prepartion method and application | |
| CN1258372C (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
| CN1803182A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1895540A (en) | Medicinal composition for treating cardiovascular disease, its making method and use | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1682970A (en) | Method for preparing herb of sowthistle leaf Ixeris injection | |
| CN1730023A (en) | Hepatitis virus resistant Chinese medicinal formulation and method for preparing same | |
| CN1522747A (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN1579495A (en) | Preparation of traditional Chinese medicine for treating cardio vascular disease, its preparation method and quality control method | |
| CN1562114A (en) | Medicine for treating chronic prostatitis and its preparing method | |
| CN1650919A (en) | Prescription of Chinese medicine compound preparation, its preparation method and use | |
| CN1241559C (en) | Chinese traditional medicine hypoglycemic agent and preparing process thereof | |
| CN1965849A (en) | Composition extracted from Chinese medicinals for treating coronary heart disease and method for preparing ingredients thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHENGDU DIKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: DIKANG SCIENCE AND TECHNOLOGY PHARMACEUTICAL CO., LTD., SICHUAN PROV. Effective date: 20150506 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 611731 CHENGDU, SICHUAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150506 Address after: 611731 Sichuan city of Chengdu province high tech Zone (West) No. 1 Dixon Road Patentee after: Chengdu Dikang Pharmaceutical Co., Ltd. Address before: 610041 No. four, No. two, South Ring Road, Chengdu, Sichuan, 11 Patentee before: Dikang Science and Technology Pharmaceutical Co., Ltd., Sichuan Prov. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 611731 Sichuan Chengdu high tech Zone (West District) di Kang Avenue No. 1 Patentee after: Chengdu Dikang pharmaceutical Limited by Share Ltd Address before: 611731 Sichuan Chengdu high tech Zone (West District) 1 Patentee before: Chengdu Dikang Pharmaceutical Co., Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060705 Assignee: YAAN XUNKANG MEDICINE Co.,Ltd. Assignor: Chengdu Di Kang medicine companies LLC Contract record no.: X2021510000036 Denomination of invention: The invention relates to a pharmaceutical composition for treating hepatitis and a preparation method and application thereof Granted publication date: 20090506 License type: Common License Record date: 20210915 |
|
| EE01 | Entry into force of recordation of patent licensing contract |